Therapy Detail

Filtering

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Drug Name	Trade Name	Synonyms	Drug Classes	Drug Description
Enfortumab vedotin-ejfv	Padcev	AGS-22ME\|Enfortumab vedotin\|AGS-22M6E\|ASG-22CE	NECTIN4 Antibody 11	Padcev (enfortumab vedotin-ejfv) is an antibody-drug conjugate (ADC) that fuses together a human antibody against NECTIN4 and monomethyl auristatin E, which may result in inhibition of tumor growth and tumor regression (PMID: 27013195). Padcev (enfortumab vedotin-ejfv) is FDA approved for use in patients with locally advanced or metastatic urothelial cancer who have previously received a PD-1 or PD-L1 inhibitor, and a platinum-containing chemotherapy, or who are ineligible for cisplatin-containing chemotherapy and have previously received one or more prior lines of therapy, in combination with Keytruda (pembrolizumab) for patients with locally advanced or metastatic urothelial carcinoma ineligible for cisplatin-containing chemotherapy, and in combination with Keytruda (pembrolizumab) or Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph) as neoadjuvant treatment for cisplatin-ineligible patients with muscle invasive bladder cancer (FDA.gov).
Pembrolizumab	Keytruda	MK-3475	Immune Checkpoint Inhibitor 150 PD-L1/PD-1 antibody 132	Keytruda (pembrolizumab) is an antibody against PD-1 that activates T-cell mediated anti-tumor immune response (PMID: 25977344). Keytruda (pembrolizumab) is approved in melanoma, SCLC, HNSCC, classical Hodgkin Lymphoma, PMBL, urothelial carcinoma, HCC, Merkel cell carcinoma, NMIBC, cutaneous SCC, MSI-H or dMMR or TMB high advanced solid tumors, NSCLC and CD274 (PD-L1)-positive NSCLC, esophageal SCC, cervical cancer, HNSCC, and TNBC, in combination with platnum-based chemo in NSCLC, with pemetrexed and platinum in pleural mesothelioma and non-sNSCLC with no EGFR or ALK mutations, with carboplatin and paclitaxel/nab-paclitaxel in sNSCLC, with axitinib or lenvatinib in RCC, with lenvatinib in endometrial carcinoma that is not MSI-H or dMMR, in combination with platinum and fluoropyrimidine-based chemo for esophageal or gastroesophageal carcinoma, in combination with Herceptin (trastuzumab), fluoropyrimidine- and platinum-containing chemo for CD274 (PD-L1)-positive, HER2-positive gastric or GEJ adenocarcinoma, in combination with fluoropyrimidine- and platinum-containing chemo for HER2-negative gastric or GEJ adenocarcinoma, in combination with platinum-based chemotherapy, with or without bevacizumab, for patients with CD274 (PD-L1)-positive (CPS>=1) cervical cancer, in combination with gemcitabine and cisplatin for biliary tract cancer, in combination with chemoradiation for cervical cancer, and in combination with carboplatin and paclitaxel for endometrial carcinoma (FDA.gov).

Filtering

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile	Indication/Tumor Type	Response Type	Therapy Name	Approval Status	Evidence Type	Efficacy Evidence	References

Filtering

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Clinical Trial	Phase	Therapies	Title	Recruitment Status	Covered Countries	Other Countries
NCT06356155	Phase II	Enfortumab vedotin-ejfv + Pembrolizumab	Study of Neoadjuvant Enfortumab Vedotin and Pembrolizumab in Cisplatin-eligible Upper Tract Urothelial Cancer (NEPTUNE)	Recruiting	USA	0
NCT05756569	Phase II	Enfortumab vedotin-ejfv + Pembrolizumab	Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology	Recruiting	USA	0
NCT06906822	Phase II	Enfortumab vedotin-ejfv + Pembrolizumab	PLUG-IN: Pembrolizumab Combined With Enfortumab Vedotin for Advanced Melanoma Patients (PlugIN)	Recruiting	ESP	0
NCT06764095	FDA approved	Enfortumab vedotin-ejfv + Pembrolizumab	Enfortumab Vedotin and Pembrolizumab Followed by Cystectomy And/or Ureterectomy for the Treatment of Locally Advanced or Metastatic Bladder and Upper Urothelial Tract Cancer, CAST-AI Trial	Recruiting	USA	0
NCT06493552	Phase II	Pembrolizumab + sEphB4-HSA Pembrolizumab Enfortumab vedotin-ejfv + Pembrolizumab Cisplatin + Gemcitabine	Modular Trial of sEphB4-HSA in EphrinB2-High Solid Tumors	Recruiting	USA	0
NCT05239624	Phase II	Enfortumab vedotin-ejfv + Pembrolizumab	Enfortumab Vedotin and Pembrolizumab in People With Bladder Cancer	Recruiting	USA	0
NCT07087860	Phase II	Enfortumab vedotin-ejfv + Pembrolizumab	Therapeutic Plasma Exchange With Enfortumab Vedotin and Pembrolizumab for Treatment of Bladder Cancers (RECIPE-B1)	Recruiting	USA	0
NCT06041503	Phase II	Enfortumab vedotin-ejfv Enfortumab vedotin-ejfv + Pembrolizumab	Enfortumab Vedotin With or Without Pembrolizumab in Rare Genitourinary Tumors	Not yet recruiting	USA	0
NCT05656235	Phase II	Enfortumab vedotin-ejfv + Pembrolizumab	Renal Retention in High Grade Upper Tract Urothelial Cancer	Recruiting	USA	0
NCT05845814	Phase Ib/II	Enfortumab vedotin-ejfv + MK-4280A Enfortumab vedotin-ejfv + MK-7684A Enfortumab vedotin-ejfv + Pembrolizumab	A Study of Efficacy and Safety of Pembrolizumab Plus Enfortumab Vedotin (EV) +/- Investigational Agents in First-Line Metastatic Urothelial Carcinoma (mUC) (MK-3475-04B/KEYMAKER-U04)	Active, not recruiting	USA \| NLD \| ITA \| ISR \| GBR \| FRA \| ESP \| CAN \| AUS	3
NCT06470282	Phase Ib/II	Enfortumab vedotin-ejfv + Pembrolizumab	Enfortumab Vedotin and Pembrolizumab Combined With Radiotherapy in Muscle Invasive Bladder Cancer	Recruiting	USA	0
NCT07183319	Phase II	Enfortumab vedotin-ejfv + Pembrolizumab Pembrolizumab	Circulating Tumor DNA Response In Urothelial Cancer	Recruiting	USA	0
NCT04700124	Phase III	Enfortumab vedotin-ejfv + Pembrolizumab Cisplatin + Gemcitabine	Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304) (KEYNOTE-B15)	Active, not recruiting	USA \| ROU \| POL \| ITA \| ISR \| HUN \| HRV \| GRC \| GBR \| FRA \| ESP \| DEU \| CZE \| CAN \| BGR \| AUS \| ARG	12
NCT06302569	Phase II	Enfortumab vedotin-ejfv + Pembrolizumab	Pembrolizumab Plus Enfortumab Vedotin in Collecting Duct and Renal Medullary Carcinoma (REPRINT)	Recruiting	ITA	0
NCT05775471	Phase II	Enfortumab vedotin-ejfv + Pembrolizumab	Pembrolizumab and Enfortumab Vedotin With Pembrolizumab Prior to and After Radical Nephroureterectomy for High-Risk Upper Tract Urothelial Cancer	Recruiting	USA	0
NCT04223856	Phase III	Carboplatin + Enfortumab vedotin-ejfv + Pembrolizumab Cisplatin + Gemcitabine Carboplatin + Gemcitabine Enfortumab vedotin-ejfv + Pembrolizumab Cisplatin + Enfortumab vedotin-ejfv + Pembrolizumab	Enfortumab Vedotin and Pembrolizumab, With or Without Chemotherapy, vs. Chemotherapy Alone in Untreated Locally Advanced or Metastatic Urothelial Cancer (EV-302)	Active, not recruiting	USA \| TUR \| POL \| NLD \| ITA \| ISR \| HUN \| GBR \| FRA \| ESP \| DNK \| DEU \| CZE \| CHE \| CAN \| BEL \| AUS \| ARG	7
NCT06809140	Phase II	Enfortumab vedotin-ejfv + Pembrolizumab	Enfortumab Vedotin Plus Pembrolizumab with Selective Bladder Sparing for Treatment of Muscle-invasive Bladder Cancer	Recruiting	USA	0
NCT05923190	Phase II	Enfortumab vedotin-ejfv Enfortumab vedotin-ejfv + Pembrolizumab	Enfortumab Vedotin Schedule De-escalation in Metastatic Urothelial Carcinoma	Recruiting	USA	0
NCT07221942	Phase II	Enfortumab vedotin-ejfv + Pembrolizumab	Pembrolizumab Maintenance After Enfortumab Vedotin (EV)/Pembro Induction in Front-Line Metastatic Urothelial Carcinoma	Not yet recruiting	USA	0
NCT07218380	Phase III	Enfortumab vedotin-ejfv + LOXO-435 + Pembrolizumab Enfortumab vedotin-ejfv + Pembrolizumab	A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract (FORAGER-2)	Not yet recruiting	USA \| TUR \| POL \| NLD \| ITA \| HUN \| GBR \| FRA \| ESP \| DNK \| DEU \| CZE \| CAN \| BRA \| AUS	4

Therapy Detail

Contact

Filtering

Sorting

Filtering

Sorting

Filtering

Sorting

Additional content available in CKB BOOST